Initial guidelines on next phase of vaccination starting on 1st March.
Important read.
✅ Eligible groups: (a) All citizens above 60 yrs. of age. (b) Those between 45 to 59 yrs of age, but with SPECIFIC COMORBIDITIES.
✅ Empanelled private sector hospitals to be included.
1/n
✅ 3 Modes of registration:
➡️ Advance Self Registration: Prior registration using CoWIN 2.0 app (yet to be available for public?).
➡️ On-site Registration: Walk-in registration at vaccination centers.
➡️ Facilitated Cohort Registration: Specific groups mobilized by...
2/n
the state and brought to the vaccination centers.
✅ All beneficiaries, irrespective of mode of registration to carry one photo id card as per acceptable list of documents.
✅ Free at Govt. Centers.
Pvt. Centers can charge upto INR 250/dose.
3/n
✅ Will be able to select location/date based on availability in case of online registration.
✅ List of co-morbidities for 45 to 59 yrs. is attached here.
📣 Wait for CoWIN 2.0 to be launched for public. State governments should put out specific information in coming days.
4/n
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Experience of a volunteer in our team who was able to book vaccination appointment on cowin.gov.in today:
➡️ Accessed the website few minutes past 9am. Entered mobile number to receive OTP.
➡️ Initially there was a delay in receiving the OTP.
1/n
➡️ The website took quite a while to move from the first screen to the next where OTP could be entered.
➡️ Received the OTP after a wait of 5 to 10 minutes. This looked to be an initial issue. Subsequent requests for OTP happened without delays.
2/n
➡️ Was presented with a screen to enter details of vaccine beneficiary. The data entry was straightforward with ID card type, number, name gender and year of birth required to be entered.
➡️ After doing the registration, there was option to enter additional beneficiaries.
3/n
With news of Dr. Reddy's applying for accelerated approval of 'Sputnik V' vaccine, here is a quick summary of the potential candidate:
✅ Vaccine platform: Viral vector technology using Adenovirus as the vector. Covishield uses the same platform, but there is a difference.
1/n
✅ Sputnik V uses 2 different variants of the human adenovirus for the 1st and 2nd dose, unlike Covishield where both doses use the same variant of a chimpanzee adenovirus.
✅ Who is developing this vaccine? Gamaleya Research Institute, Russia.
2/n
✅ Has the vaccine got approval in other countries? Russia stirred critical discussions when use of Sputnik V was authorized in Russia before completion of trials. Subsequently Phase 3 interim results have been published.
20+ countries have given emergency approval.
3/n
➡️ This relatively low prevalence in KL correlates with the lower case load seen in the state till August.
➡️ In Dec, the prevalence saw a multi fold increase to 11.6% (national 21%) from 0.8% in August. This is reflected in the significant spike seen in KL from September.
2/5
➡️ It is notable that in Aug, KL had a relatively low prevalence of 0.8% - reflecting the initial control of spread.
➡️ It left a high % of population vulnerable to infection, which would have contributed to the spike post August. Furthered by local body elections and Onam.
3/5
Kerala - Of delayed peak and long plateau: After reporting the 1st Covid19 case in Jan 2020, KL hit it's peak only in Oct 2020. Even till Sept., cases per million of KL remained lower than that of states like TN, KA, AP.
The story after the peak though has been different.
1/4
TN + AP peaked in Aug '20, while KA hit it's peak in Sep '20. KL had a monthly TPR of only 5.8% in September (overall TPR 4.5%), again indicating an increasing but controlled spread.
Did this relatively controlled spread for most of 2020, lead to increased cases post Sept.?
2/4
After hitting the peak, states like TN, KA and AP saw a significant decline in cases within 2 months. Unlike them, monthly cases per million and TPR have mostly plateaued in KL, without seeing a significant dip.
A combination of increased mobility, high population density,
The expert committee of CDSCO met on 30/12, 01/01 and 02/01 to deliberate on accelerated approval of vaccines. Recommendations made on each day have been officially published.
📣 In this thread, we take a look at the timeline of events that lead to the approval. Must read.
1/n
30th December: #Covaxin: Bharat Biotech presents status of Phase 3 trials and updated safety data.
📣 Committee recommends that updated safety and EFFICACY data of Phase 3 trials have to be presented for further consideration.
2/n
30th December: #Covishield: SII presents safety and efficacy data of Phase 2/3 trials from UK, Brazil, SA along with data from ongoing Indian trials. SII mentions that UK has provided EUA.
📣 Committee asks for complete details of UK approval to be submitted.
3/n